MetaCap

Inhibrx Biosciences Inc. (INBX)

NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

68.97-5.36 (-7.21%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

INBX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$9.06
52-week range
57.30 – 155.29
Day range
68.78 – 74.45
Volume / Avg
252.13K / 305.96K
Beta
—

52-week range

$57.30$155.29

INBX stock today

On Nov 20, INBX ended the session at $68.97, shedding $5.36 (7.21%), versus the S&P 500's 3.70% decline. Shares are 55.6% below their 52-week high of $155.29, set on Apr 22, 2026 and 20.4% above the 52-week low of $57.30, near the bottom of the past year's range. INBX is down 12.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 17.8%.

Inhibrx Biosciences has posted a net loss over the last twelve months (EPS of -$9.06), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Inhibrx Biosciences

Company profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Mark Paul Lappe
Headquarters
La Jolla, CA
Employees
109

Financial highlights

Full financials

In fiscal 2025, Inhibrx Biosciences generated $1.3 million in revenue, up 550.0% from fiscal 2024. Inhibrx Biosciences reported a net loss of $140.1 million, compared with net income of $1.69 billion a year earlier. Operating margin was -10386.5%.

Inhibrx Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$1.30M$200.00K$1.80M
Growth+550.00%-88.89%—
Net income$-140.06M$1.69B$-241.36M
EPS (diluted)$-9.04$112.62$-20.48

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$266.67+286.65%

  • Strong buy 0
  • Buy 3
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $230.00High $325.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-2.46 vs $-2.50
Surprise
+1.60%

INBX news

All INBX news

Inhibrx Biosciences peers

Health Care sector
INBX peer companies
CompanyPrice% ChgMarket capCompare
IMTXImmatics N.V.5.77-3.03%$878.58Mvs INBX
VORVor Biopharma Inc.19.19+3.62%$1.18Bvs INBX
TSHATaysha Gene Therapies Inc.3.72-1.33%$1.21Bvs INBX
ODTXOdyssey Therapeutics Inc.16.96-7.52%$815.23Mvs INBX
BBTXBambusa Therapeutics Inc.16.00+2.89%$815.08Mvs INBX
NVAXNovavax Inc.7.47-3.24%$1.23Bvs INBX
PRMEPrime Medicine Inc.3.55-7.55%$791.62Mvs INBX
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs INBX

Indexes, lists and sector

Inhibrx Biosciences stock FAQ

What is Inhibrx Biosciences's stock price today?

INBX last traded at $68.97 as of Nov 20, 4:00 PM EST, down 7.21% on the day. Prices are delayed at least 15 minutes.

Who is Inhibrx Biosciences's CEO?

Mr. Mark Paul Lappe is the chief executive officer of Inhibrx Biosciences Inc., which has about 109 employees.

What is the INBX 52-week high?

The 52-week high for INBX is $155.29 and the 52-week low is $57.30. The stock is currently 55.6% below its high.

Compare INBX